Life-expectancy gains from pharmaceutical drugs: A critical appraisal of the literature

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 9, Issue 4, 2009, Pages 353-364

  Grootendorst, Paul ^a,b   Piérard, Emmanuelle ^c   Shim, Minsup ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF WATERLOO   (Canada)

Author keywords

Aggregate data; Health outcome; Infant mortality; Life expectancy; Pharmaceutical expenditure; Sensitivity analysis

Indexed keywords

ARTICLE; CIGARETTE SMOKING; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; LIFE EXPECTANCY; MATHEMATICAL ANALYSIS; MEDICAL LITERATURE; MORTALITY; OUTCOME ASSESSMENT; PHARMACY; PREDICTION; PRODUCTIVITY; SENSITIVITY ANALYSIS; CLINICAL TRIAL; FEMALE; MALE; REGRESSION ANALYSIS; STATISTICAL MODEL;

DRUG;

CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; LIFE EXPECTANCY; MALE; MODELS, ECONOMETRIC; MODELS, STATISTICAL; PHARMACEUTICAL PREPARATIONS; REGRESSION ANALYSIS;

EID: 70350434556     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.09.35     Document Type: Article

References (31)

1. Beaudet MP, Tully P, St-Arnaud J. Life expectancy. Health Rep. 17(1), 43-47 (2005).
2. Statistics Canada. Life Expectancy, Abridged Life Table, at Birth and at Age 65, by Sex, Canada, Provinces and Territories, Annual (Years) (CANSIM Table 102-0511). Statistics Canada, Ottawa, Canada (2008).
3. Cutler D, Deaton A, Lleras-Muney A. The determinants of mortality. J. Econ. Persp. 3, 97-120 (2006).
4. Welsfeldt ML, Sleman SJ. Advances in the prevention and treatment of cardiovascular disease. Health Affairs 26(1), 25-37 (2007).
5. Lichtenberg FR. The effect of new drug approvals on HIV mortality in the US, 1987-1998. Econ. Hum. Biol. 1(2), 259-266 (2003). ••Reviews the effect of pharmaceutical expenditures and new drugs adoption on HIV mortality in the USA and finds that they decrease mortality due to the disease.
6. Lichtenberg FR. Sources of U.S. longevity increase, 1960-2001. Q. Rev. Econ. Finance 44, 369-389 (2004).
7. Crémieux PY, Meilleur MC, Ouellette P et al. Public and private pharmaceutical spending as determinants of health outcomes in Canada. Health Econ. 14(2), 107-116 (2005). ••Only Canadian study of the effect of pharmaceutical spending on infant mortality and life expectancy. Found that small changes in pharmaceutical spending had large effects on health outcomes. (Pubitemid 40253626)
8. Crémieux PY, Meilleur MC, Ouellette P et al. Erratum: public and private pharmaceutical spending as determinants of health outcomes in Canada. Health Economics 14(2), 107-116 (2005). ••Only Canadian study of the effect of pharmaceutical spending on infant mortality and life expectancy. Found that small changes in pharmaceutical spending have large effects on health outcomes. (Pubitemid 40253626)
9. Frech HE, Miller RD. The effects of pharmaceutical consumption and obesity on the quality of life in the OECD countries. Pharmacoeconomics 22(2, Suppl. 2), 25-36 (2004). ••International comparison of the effect of pharmaceutical spending across Organisation for Economic Co-operation and Development countries on health outcomes and allow pharmaceutical spending to affect future health rather than current health as most other studies do.
10. Shaw JW, Horrace WC, Vogel RJ. The determinants of life expectancy: an ana lysis of the OECD health data. South. Econ. J. 71(4), 768-783 (2005). ••International comparison of the effect of pharmaceutical spending across on Organisation for Economic Co-operation and Development countries on health outcomes and allow pharmaceutical spending to affect future health rather than current health as most other studies do.
11. Viscusi WK, Aldy JE. The value of a statistical life: a critical review of market estimates throughout the world. J. Risk Uncertain. 27(1), 5-76 (2003).
12. Babazono A, Hillman AL. A comparison of international health outcomes and health care spending. Int. J. Technol. Assess. Health Care 10, 376-381 (1994). (Pubitemid 24222537)
13. Liu L, Cline RR, Schondelmeyer SW, Schommer JC. Pharmaceutical expenditures as a correlate of population health in industrialized nations. Ann. Pharmacother. 42(3), 368-374 (2008).
14. Morgan S. Price and Productivity Measurement in a Pharmaceutical Sector Sub-market: the Real Cost of Treating Hypertension. Working Paper. University of British Columbia Centre for Health Services and Policy Research, BC, Canada (2001).
15. Gerdtham UG, Jonsson B. International comparisons of health expenditure: theory, data and econometric ana lysis. In: Handbook of Health Economics (Vol. 1A). Culyer AJ, Newhouse JP (Eds). Elsevier Science, Amsterdam, The Netherlands (2000). •Excellent exposé of the challenges of making international comparisons of healthcare systems, in particular when comparing healthcare expenditures.
16. Fuchs VR, Sox HC. Physicians' views of the relative importance of thirty medical innovations. Health Affairs 20(5), 30-42 (2001).
17. Akkoyunlu S, Lichtenberg FR, Siliverstovs B et al. Spurious Correlation in Estimation of the Health Production Function: a Note. Working Paper No. 0903. University of Zurich, Socioeconomic Institute, Zurich, Switzerland (2009).
18. Granger CWJ. Empirical Modelling in Economics. Cambridge University Press, Cambridge, UK (1999).
19. Neumann PJ, Sandberg EA, Bell CM, Stone PW, Chapman RH. Are pharmaceuticals cost-effective? A review of the evidence. Health Affairs 19(2), 92-109 (2000).
20. Gravelle H, Backhouse M. International cross-section ana lysis of the determination of mortality. Soc. Sci. Med. 25(5), 427-441 (1987).
21. Nixon J, Ulmann P. The relationship between health care expenditure and health outcomes. Evidence and caveats for a causal link. Eur. J. Health Econ. 7(1), 7-18 (2006). (Pubitemid 43375568)
22. Guindon GE, Contoyannis P. A second look at pharmaceutical spending as determinants of health outcomes in Canada. Health Economics DOI: 10.1002/ hec.1415 (2008). ••Very well-researched and detailed critique of the article by Crémieux, Meilleur, Ouellette et al.
23. Martin S, Rice N, Smith PC. Does health care spending improve health outcomes? Evidence from English programme budgeting data. J. Health Econ. 27(4), 826-842 (2008). •Example of a study using disease-specific data to evaluate the cost of a life-year saved, which is probably a better avenue than studies using general data on aggregate health status measures.
24. Lichtenberg FR. Have newer cardiovascular drugs reduced hospitalization? Evidence from longitudinal country-level data on 20 OECD countries, 1995-2003. Health Econ. 18(5), 519-534 (2008).
25. Hollis A, Pogge T. The Health Impact Fund: Making New Medicines Accessible to All. Incentives for Global Health, Yale University, CT, USA (2008). www.yale.edu/macmillan/igh/hif-book.pdf
26. Canadian Institute for Health Information, National Health Expenditures Trends http://secure.cihi.ca/cihiweb/products/national-health-expenditure- trends-1975-2006-e.pdf
27. Statistics Canada, E-Stat http://estat.statcan.ca/cgi-win/CNSMCGI.EXE? LANG=E&CIITables=2966&ResultTemplate=ESTAT\CII-FLST&ROOTDIR=ESTAT/ &LangFldr=English/&C2DB=
28. OECD Health Data 2007 www.sourceoecd.org/vl=2159454/cl=16/ nw=1/rpsv/ij/oecdstats/99991012/ v1n1/s1/p1
29. Centers for Disease Control and Prevention, National Center for Health Statistics www.cdc.gov/nchs/data/hus/hus06. pdf#027
30. US Food and Drug Administration, Center for Drug Evaluation and Research, New Molecular Entity (NME) Drug and New Biologic Approvals www.fda.gov/cder/ rdmt/default.htm
31. Centers for Medicare & Medicaid Services, Office of the Actuary, National Health Statistics Group, National health accounts www.cms.hhs.gov/ NationalHealthExpendData/02-NationalHealthAccountsHistorical.asp#TopOfPage